Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
DRDs(Dopamine receptors) | 1 |
Target |
Mechanism ADRA2 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date16 May 2018 |
Target |
Mechanism DRDs agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date28 May 2001 |
Target- |
Mechanism Cell membrane permeability enhancers |
Active Org.- |
Originator Org. |
Active Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date13 Jul 2023 |
Sponsor / Collaborator |
Start Date06 Jul 2021 |
Sponsor / Collaborator |
Start Date03 Mar 2014 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Apomorphine Hydrochloride ( DRDs ) | Parkinson Disease More | Phase 1 |
Pumactant | Asthma More | Discontinued |
Lofexidine Hydrochloride ( ADRA2 ) | Substance Withdrawal Syndrome More | Pending |